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Objective  The aim of this review was to overview the current practice of gastric cancer treatment including surgery and 
other adjuvant modalities.
Data sources  The review was based on data obtained from the published articles and main guidelines in the East and 
West.
Study selection  Articles with high level of evidence or current best evidence in each issue were selected to be reviewed.
Results  Although varied adjuvant modalities have been proved to be benefit for treating gastric cancer, surgery is still the 
most important treatment strategy against gastric cancer. Actively adapting to new technology is important but it should be 
balanced with an effort to establish sound scientific rationale that adheres to oncologic principles.
Conclusions  Future treatment of gastric cancer will be focused on tailored, personalized therapy. For achieving it, 
collaboration across disciplines is essential. Also the philosophy of caring for the patients with gastric cancer should be 
rooted in the realization of true patient benefit regardless of who is providing the care. With these philosophies, we can 
shift the scientific and technological advances toward triumph over gastric cancer.
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Gastric cancer is a major health issue worldwide, with 989 000 newly diagnosed cases (7.8% of the total 
malignancy) and 737 000 deaths annually (9.7% of total 
cancer deaths).1 Half of all gastric cancer patients are from 
Eastern Asia (463 000 gastric cancer patients in China 
alone), and approximately two-thirds of all cases occur in 
developing countries.
Gastrectomy with lymph node dissection has been 
established as a standard treatment for gastric cancer.2 
Traditionally, the surgeon assumes responsibility in 
determining operability and the extent of surgery required 
using histologic and radiologic information. With recent 
advances in both knowledge and available technology, 
however, therapeutic strategies for gastric cancer have 
been diversified. Surgical instruments and devices have 
been improved, and chemotherapeutic drugs as well as 
targeted agents have become more advanced as we gain a 
more comprehensive understanding of cancer biology. The 
epidemiology of gastric cancer has also been changing due 
to mass screening programs and improved survival rates. 
Further, recent progress in molecular biology research has 
been promising for personalized cancer therapy. In this new 
era, the role of physicians who treat gastric cancer is to 
rapidly translate these advances, thereby providing the best 
possible patient care.
This review focuses on basic oncologic and technical 
principles of gastric cancer surgery to date. We also discuss 
adjuvant modalities for treatment of gastric cancer and the 
future directions of these treatments.
Basic oncologic principle of gastric cancer surgery
Complete surgical resection of macro and microscopic 
tumors (R0) with en-block lymphadenectomy is the gold 
standard for cancer treatment. In patients with gastric 
cancer, radical gastrectomy is considered to be the only 
curative treatment option. In order to realize the clinical 
benefits of this definitive surgery, several oncologic 
principles should be maintained. During surgery, frequent 
manipulation of the tumor itself could lead to direct spillage 
of tumor cells.3 Thus, a “no touch technique” that entails 
wrapping the lesion, especially in cases of serosa-positive 
tumors, to prevent iatrogenic peritoneal seeding during the 
operation should be applied. Also, careful hemostasis to 
avoid bleeding and lymphatic leakage is important as well.
Lymph node dissection for gastric cancer surgery
Gastric cancer can spread along both the lesser and greater 
curvatures of the stomach via an abundant and complicated 
lymphatic network system. Thus, standard lymph node 
dissection is essential during radical gastrectomy. The 
extent of lymph node dissection in cases of gastric cancer 
is determined via the D-level criteria, while the D level is 
decided according to the type of gastrectomy performed. 
N1 lymph nodes commonly refer to the lymph nodes 
around the stomach, while N2 lymph nodes refer to those 
around the major vessels that supply blood to the stomach.4 
Thus, D1 gastrectomy refers to gastrectomy with lymph 
node dissection at the N1 level only, while D2 lymph node 
dissection indicates removal of lymph nodes at the N2 
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level.
The appropriate extent of lymph node dissection for gastric 
cancer treatment has long been debated. Japanese surgeons 
previously proposed that more extensive lymph node 
dissection leads to an improved survival benefit in patients 
with advanced gastric cancer (AGC). Under this premise, 
D3 lymph node dissections (D2 lymph node dissection 
including para-aortic area) were routinely performed. More 
recently, however, a prospective randomized controlled 
study by Japanese researchers showed that D3 surgery 
was associated with more complications without survival 
benefit compared with D2 surgery.5,6 Based on these 
randomized clinical trial results, D2 lymphadenectomy has 
been adopted as the standard of care in Eastern countries.
In the 1990s, phase III randomized controlled trials 
(RCTs) in Western countries showed that D2 lymph node 
dissection did not offer a survival benefit over D1,7,8 
but was associated with a higher incidence of surgery-
related morbidity and mortality. Consequently, limited 
D0 or D1 lymph node dissection with perioperative 
chemotherapy or postoperative chemoradiotherapy was 
adopted as the standard of care in Western countries.9-12 A 
subsequent Dutch trial that included 15 years of follow-
up data, however, showed that D2 lymph node dissection 
was beneficial in terms of preventing loco-regional 
recurrence and gastric cancer-related death compared with 
D1 surgery.13 In addition, an RCT from Taiwan reported 
a survival benefit without any surgery-related mortality 
in patients who underwent D2 lymph node dissection.14 
Currently, the most commonly used Western guidelines, 
the National Comprehensive Cancer Network (NCCN) 
and European Society for Medical Oncology guidelines, 
recommend D2 gastrectomy as the standard of care when 
performed at specialized centers only15,16 due to the high 
rates of morbidity and mortality when performed by 
inexperienced surgeons.
Omentectomy with bursectomy
The omentum is a visceral peritoneum which hangs from 
the stomach and defends against inflammation within the 
abdominal cavity.17 The omentum has milky spots which 
act as a gateway for cancer seeding in the early stages 
of peritoneal metastasis.18 Therefore, complete removal 
of the greater omentum is considered to be essential for 
successful gastric cancer surgery. Recent studies have 
reported that outcomes were similar between partial and 
complete omentectomy in patients with early gastric cancer 
(EGC)19 as well as AGC.20 However, the safety of partial 
omentectomy for AGC has yet to be confirmed by an RCT. 
Thus the current Japanese guidelines recommend complete 
removal of the greater omentum when gastric cancer invades 
the subserosal layer (T3) and permits partial omentectomy, 
preserving a 3 cm distal portion of the gastroepiploic arcade 
if invasion involves less than the proper muscle layer.4
Dissection and removal of the anterior membrane of the 
transverse mesocolon with the capsule of pancreas, also 
known as “bursectomy”, has been considered the standard 
procedure in conjunction with total omentectomy during 
radical gastrectomy for AGC in Eastern countries.21 The 
reasoning behind this procedure is that removing the 
membrane that covers the posterior stomach cavity which 
may include free cancer cells or micrometastasis could 
decrease cancer recurrence.22 It was previously suggested 
that bursectomy was a futile procedure without clinical 
benefit23 and a recent NCCN guideline excluded bursectomy 
from the definition of D2 dissection.15 However, based 
on the interim results of an RCT conducted in Japan,24,25 
bursectomy is recommended for serosa-positive gastric 
cancer because it could offer survival benefit.4 Long-term 
follow-up results and the on-going large-scale multicenter 
RCT (JCOG 1001) will provide more concrete evidence on 
this issue in the future.
Organ-preserving gastrectomy
Historically, surgeons thought that pancreatico-splenectomy 
should be performed in cases of proximal gastric cancer 
since lymph nodes along the upper border of the pancreas 
and splenic hilum needed to be resected for curative 
surgery.26 Thus total gastrectomy for proximal gastric cancer 
had meant total gastrectomy with distal pancreatectomy and 
splenectomy. One of the common complications of distal 
pancreatectomy is pancreatic leak resulting in subphrenic 
abscess formation.27 In 1995, Maruyama et al28 reported that 
pancreas-preserving total gastrectomy could be performed 
with a lower incidence of morbidity and mortality. An 
RCT which compared the effects of D2 gastrectomy with 
those of D1 gastrectomy reported that splenectomy with 
lymph node dissection was associated with high morbidity 
and a worse prognosis compared to spleen- and pancreas-
preserving gastrectomy, and pancreatico-splenectomy with 
lymph node dissection had the highest morbidity and worst 
prognosis.29 In addition, Noh et al presented the technique 
of spleen-preserving total gastrectomy with splenic hilar 
lymph node dissection at the Second International Gastric 
Cancer Congress and reported that splenectomy resulted in 
poor short-term outcomes with similar long-term outcomes 
compared to spleen-preserving gastrectomy.30,31 As a result, 
splenectomy for the purpose of lymph node dissection is 
not routinely practiced in cases of proximal gastric cancer,15 
and this change has decreased the morbidity and mortality 
associated with gastrectomy. It is important, however, 
that appropriate lymph node dissection (D2 gastrectomy) 
is performed in conjunction with spleen-preserving 
gastrectomy.
Adequate resection margins
The type of gastrectomy performed is determined according 
to the location of the tumor with the goal of achieving 
an adequate macroscopic and microscopic resection 
margin. The current Japanese guidelines recommend 
a gross resection margin of greater than 2 cm for EGC 
and 3–5 cm for AGC.4 NCNN guidelines, on the other 
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hand, recommend a resection margin of 4 cm.15 If there 
is direct tumor invasion into adjacent organs such as the 
transverse colon or pancreas, en-block combined resection 
is necessary. When the resection margin is ambiguous, 
histopathologic confirmation on frozen sections is required.
Reconstruction after gastrectomy
After achieving a safe resection margin, the pathway 
for food passage should be reconstructed. The most 
commonly used reconstruction techniques are the Billroth I 
(gastroduodenostomy), Billroth II (gastrojejunostomy), and 
Roux-en-Y gastrojejunostomy (or esophagojejunostomy). 
The Billroth I anastomosis offers advantages such as 
maintenance of physiologic food passage, use of a single 
anastomosis, and simplicity of surgical technique.32 A 
recent study reported on the benefit of maintaining iron 
metabolism when a Billroth I anastomosis is utilized.33 
However, the extent of gastric resection is limited and 
at times tension at the anastomosis site is problematic. 
Anastomosis leak is one of the more serious complications 
of gastrectomy, which can have a negative impact on 
patients’ prognosis.34 To decrease the risk of leak after 
Billroth I, a modified double stapling technique which 
avoids stapling on the staple line is helpful.35
The Billroth II anastomosis permits a wider range of gastric 
resection than Billroth I and is quicker to perform than 
the Roux-en-Y reconstruction. The Billroth II technique is 
associated with postoperative reflux symptoms, however, 
and as a result may decrease the quality of life (QOL) 
of patients and increase the risk of developing cancer in 
the stomach remnant.36 The Roux-en-Y reconstruction 
was designed to reduce bile reflux, which in turn lowers 
the risk of associated gastritis or esophagitis compared 
with the Billroth methods.37,38 Roux-en-Y reconstruction 
is more time intensive, the risk of leakage is high due to 
a greater number of anastomoses, and Roux stasis can 
occur.39 A recent meta-analysis showed that Roux-en-Y 
reconstruction did not increase postoperative complications 
such as leakage,40 and an RCT reported no difference in 
postoperative QOL and nutritional status between the 
reconstruction techniques.37 Because each reconstruction 
method has its own distinct advantages and disadvantages, 
surgeons are able to tailor the treatment method to the 
needs of the patient.
Strategies for improving quality of life and 
decreasing complications
Historically, the use of large incisions, nasogastric tubes, 
and placement of drains were common practice during 
surgery for gastric cancer. This often resulted in discomfort 
for the patient, however, due to incisional pain, sore throat 
due to nasogastric tube insertion, and drain site infection. 
Consecutive studies have shown that routine insertion of 
nasogastric tubes and drains is not necessary,41,42 and that 
trimming of the lesser curvature and greater curvature using 
a “Bovie” instead of a “clamp and tie” technique can reduce 
the operative time and increase cost effectiveness.43 In 
addition, if wound traction is appropriate, a small incision 
less than 15 cm in length that does not extend below the 
umbilicus is large enough for total gastrectomy. These 
small changes may help to improve the QOL of patients 
undergoing gastrectomy for gastric cancer.
Role of minimally invasive surgery for gastric 
cancer
Minimally invasive surgery (MIS) such as laparoscopic 
or robotic surgery has become the standard procedure in 
many surgical fields including oncologic surgery. In gastric 
cancer patients, laparoscopic distal gastrectomy with 
lymph node dissection44 has become widely used for EGC 
without evidence of lymph node metastasis, especially in 
Korea and Japan. Although the short-term benefits such as 
small incision size, improved QOL, and shorter hospital 
stay are well established,45,46 there have been concerns that 
MIS does not achieve adequate D2 lymph node dissection. 
Thus, to evaluate the oncologic safety of laparoscopic 
gastrectomy for EGC, multicenter randomized trials are 
ongoing in both Korea (KLASS trial)46 and Japan (JCOG 
0912 trial).47 While several studies48,49 have reported that 
laparoscopic gastrectomy offers similar long-term outcomes 
to those of open gastrectomy for EGC, results from these 
ongoing trials are needed for further confirmation. To 
evaluate whether laparoscopic gastrectomy can be used in 
cases of AGC, a multicenter RCT (KLASS II) is ongoing in 
Korea.
Robotic surgery has several potential advantages over 
laparoscopic surgery including three-dimensional viewing, 
a tremor filter, and articulated movements of robotic 
arms.50,51 Several recent studies have reported that robotic 
gastrectomy was associated with less blood loss and 
decreased incidence of ileus or obstruction than open or 
laparoscopic gastrectomy during short-term follow-up.52,53 
The cost of robotic surgery is very high, however, and the 
practical advantages over laparoscopic surgery have yet 
to be proven. Moreover there have been no studies that 
have examined long-term outcomes. Thus, future trials are 
needed to further assess the role of robotic surgery in the 
treatment of gastric cancer.
The development of endoscopic mucosal resection has 
transformed the role of endoscopy from a diagnostic tool 
into a treatment option for gastric cancer. Endoscopic 
submucosal dissection permits complete removal of large, 
deep tumors due to advanced endoscopic instruments and 
techniques when the probability of lymph node metastasis 
is very low.54,55 Because endoscopic treatment has the 
advantage of not requiring gastrectomy, its indications have 
been expanded.4,56 This technique carries its own risks, 
however, including gastric perforation and bleeding.57 
Additionally, the long-term oncologic outcomes of 
endoscopic treatment of gastric cancer have not yet been 
established. As a result, surgical resection with adequate 
lymph node dissection remains the standard treatment 
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for EGC yet. In the future, with the development of tools 
which can clearly identify whether there are lymph node 
metastases, the use of endoscopic treatment could be 
greatly expanded.
Sentinel lymph node navigation and tailored 
surgical approaches
Although radical gastrectomy with D2 lymph node 
dissection is the standard surgical treatment for AGC, more 
extensive lymph node dissection results in greater morbidity 
and mortality,7,8,29 and gastrectomy itself could decrease 
the QOL of patients. Therefore, if we can predict the status 
of the primary tumor and regional lymph nodes before the 
operation, tailored gastrectomy such as wedge resection 
and limited lymph node dissection may be possible.
Sentinel lymph node biopsy for predicting whether there 
are metastatic lymph nodes has been widely used in patients 
with breast cancer and melanoma. In patients with gastric 
cancer, the use of sentinel lymph node biopsy to establish 
a tailored surgical approach for lymph node-negative EGC 
has been studied. This method is not widely used to date, 
however, since there are no established data regarding 
standardized techniques or accuracy. Fluorescent surgical 
imaging has recently emerged as well and has been widely 
studied in other types of cancers in combination with 
laparoscopic or robotic surgery.58-62 This new technique is 
expected to guide the possibility of tailored, limited surgery 
for gastric cancer.
Adjuvant therapy for gastric cancer
Surgery is the oldest but most important treatment strategy 
for patients with gastric cancer, without which patients 
rarely get cured. In conjunction with surgery, additional 
adjuvant treatment strategies such as chemotherapy and 
radiotherapy help to increase the chance of cure.
In Eastern countries, many surgeons believed that D2 
gastrectomy alone can cure gastric cancer, since results 
from those patients were better than those of Western 
countries that utilized surgery combined with perioperative 
chemotherapy or postoperative chemoradiation therapy. 
However, others were curious about the effect of adjuvant 
chemotherapy after D2 gastrectomy, and a large patient-
level meta-analysis by the GASTRIC group suggested 
that postoperative adjuvant chemotherapy may have a 
survival benefit compared with surgery alone.63 To test 
this hypothesis, two monumental phase III multicenter 
RCTs were conducted: the Adjuvant Chemotherapy Trial 
of S-1 for Gastric Cancer (ACTS-GC) in Japan64,65 and the 
Capecitabine and Oxaliplatin Adjuvant Study in Stomach 
Cancer (CLASSIC) in multiple Eastern countries.66
The results of the ACTS-GC trial showed that adjuvant 
S-1 chemotherapy after D2 gastrectomy had a survival 
benefit in terms of overall survival and relapse-free 
survival compared with surgery alone. As a result, the 
latest Japanese Gastric Cancer Association treatment 
guidelines4 recommend adjuvant S-1 chemotherapy as a 
standard regimen for patients with stage II or III gastric 
cancer (according to Japanese classification).67 The interim 
results of the CLASSIC trial supported the positive effects 
of adjuvant chemotherapy with the XELOX regimen 
(capecitabine with oxaliplatin) after D2 gastrectomy. Their 
results showed that adjuvant XELOX after D2 gastrectomy 
resulted in better 3-year disease-free survival compared 
with the group that underwent surgery alone.
Although D2 gastrectomy is now recommended by 
Western guidelines,15,16 it has not been a practical standard 
surgery due to its high morbidity and mortality. Thus, 
the role of perioperative chemotherapy or postoperative 
chemoradiation therapy with a more limited surgery has 
been evaluated and practiced in Western countries. In 
Europe, based on the Medical Research Council Adjuvant 
Gastric Infusional Chemotherapy trial (MAGIC trial),9 
perioperative chemotherapy in conjunction with surgery 
has been the standard treatment for AGC. Their results 
showed that perioperative chemotherapy improved not 
only resectability, but also disease-free survival and 
overall survival compared to surgery alone. However, this 
study was limited by the inclusion of patients with lower 
esophageal cancer and esophago-gastric junction cancer. 
Additionally, the trial lacked a standard preoperative 
staging system.
In the United States, adjuvant chemoradiation therapy 
after gastrectomy with limited lymph node dissection (D0 
or D1) has been the standard treatment for AGC based 
on the results of the intergroup 0116 trial.10,11 That study 
showed promising results using chemoradiation therapy 
after surgery, with better overall survival and relapse-free 
survival compared with the surgery alone group. The role of 
radiation is to control loco-regional tumors after insufficient 
lymph node dissection. However, Eastern studies have 
shown that appropriate lymph node dissection (D2 
dissection) can offer controlled loco-regional tumor growth 
with lower morbidity and mortality than chemoradiation 
therapy after surgery. Thus the effects of radiation therapy 
after D2 gastrectomy were thought to be negative, and this 
has been supported by the results of a clinical trial from 
Korea (the Adjuvant Chemoradiation Therapy in Stomach 
Cancer, ARTIST trial).68 However, there have been some 
suggestions from Eastern studies that radiotherapy would 
be helpful in decreasing logo-regional recurrence in 
specific patients even after D2 gastrectomy.69,70 A recent 
study reported that radiation therapy after D2 gastrectomy 
with chemotherapy improves loco-regional recurrence-free 
survival compared with D2 gastrectomy with chemotherapy 
in patients with stage III gastric cancer.71 To determine the 
efficacy of radiation therapy after D2 gastrectomy, further 
RCTs are needed.
Prognosis and treatment responses are sometimes different 
even within groups of patients with the same stage of 
cancer. Thus, further understanding of cancer biology will 
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help to develop new strategies for approaching gastric 
cancer. The Trastuzumab for Gastric Cancer (ToGA) trial72 
showed potential success for targeted therapy in gastric 
cancer, which has encouraged investigators to seek other 
targeted biological pathways. Trastuzumab (Herceptin) is 
a humanized monoclonal antibody which interferes with 
human EGFR type 2 (HER-2/neu, ErbB-2). The ToGA trial 
showed that trastuzumab combined with chemotherapy 
provides a survival benefit in patients with HER-2-positive 
AGC. Recent advances in genomics and multiomics-based 
high-throughput biology are helping to pave a new road 
toward personalized cancer treatment. Molecular assays 
as well as integrated genomic scale data will allow for 
tailoring of the therapeutic decision-making process for 
patients within the same TNM stage groups.
Although adjuvant treatment strategies for gastric cancer 
are far more advanced today than in past decades, the 
quality of surgery still strongly affects patient survival. 
Thus, it is important to not only identify specific indications 
for various adjuvant therapies and new treatment strategies, 
but also standardize the type of gastric cancer surgery as 
D2 gastrectomy.
Concluding remarks
In recent years, we have made great strides in the treatment 
of gastric cancer. Surgical treatment of gastric cancer has 
improved and been standardized, and new technologies 
and instruments are continuously being developed and 
adapted. In order to achieve minimal invasiveness, the 
roles of endoscopic, laparoscopic, and robotic approaches 
have been evaluated and established, and the indications 
for chemotherapy and radiation therapy have also been 
determined. Actively adapting to new technology is an 
important part of delivering optimal care in patients with 
gastric cancer, though this should be balanced with an 
effort to establish sound scientific rationale that adheres to 
oncologic principles.
In the future, treatment of gastric cancer will be focused on 
tailored, personalized therapy. To achieve this, collaboration 
across disciplines will be necessary. Thus surgeons and 
physicians should envision a future featuring genomic 
precision oncology. The philosophy of caring for patients 
with gastric cancer should be rooted in the realization of 
true patient benefit regardless of who is providing the care. 
If we keep these philosophies in mind, we can shift these 
scientific and technological advances toward triumph over 
gastric cancer.
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